TransThera Sciences Nanjing Inc is a China-based company principally engaged in the research and development of small molecule innovative drugs. The Company focuses on tumor and immunity field. The Company's research projects are TT-00420, TT-00434, TT-00920 and so on. Its business covers project research phase, project development phase and project clinical phase.

Employees

121

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/01/26	95.50 $	+0.26%	2,576,044
15/01/26	95.25 $	-4.85%	1,170,075
14/01/26	100.10 $	-11.57%	2,930,098
13/01/26	113.20 $	+0.09%	1,534,600
12/01/26	113.10 $	-1.57%	748,546

Delayed Quote Hong Kong S.E., January 16, 2026 at 08:08 am

More quotes

Income Statement and Estimates

More financial data

Market Closed - Hong Kong S.E. Other stock markets 08:08:25 16/01/2026 GMT			5-day change	1st Jan Change
95.50 ^HKD	+0.26%		-15.56%	-16.88%

01-14	TransThera Sciences (Nanjing) to place 2.1 million shares at HK$92.85 per share	RE
01-14	TransThera Sciences Seeks HK$195 Million via Share Offering	MT

01-14	TransThera Sciences (Nanjing) to place 2.1 million shares at HK$92.85 per share	RE
01-14	TransThera Sciences Seeks HK$195 Million via Share Offering	MT
12-22	TransThera Sciences, Inc.(SEHK:2617) added to S&P Global BMI Index	CI
12-22	Certain H Shares of TransThera Sciences, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025.	CI
12-19	TransThera Sciences Nanjing, Inc. Announces New Drug Application for Tinengotinib Tablets Accepted by the National Medical Products Administration	CI
12-19	TransThera Sciences' Tinengotinib Accepted For Review	MT
12-19	Transthera Sciences (Nanjing) says NMPA accepts new drug application for tinengotinib tablets	RE
12-17	TransThera Sciences, Inc. Announces Publication of Clinical Results of Its Core Product Tinengotinib Against Cholangiocarcinoma	CI
12-04	TransThera Sciences, Inc. Announces Inclusive of Tinengotinib Tablets in the List of Products for Priority Review by the National Medical Products Administration	CI
12-04	TransThera Sciences' Tinengotinib Added to China's Priority Review List	MT
11-03	TransThera Sciences Sells NLRP3 Inhibitor License to Neurocrine Bioscience	MT
11-03	Transthera Sciences (Nanjing) Inc announces collaboration with Neurocrine Biosciences Inc for NLRP3 inhibitors	RE
11-03	TransThera Sciences, Inc. Announces Collaboration with Neurocrine	CI

1 day	+0.26%
1 week	-15.56%
Current month	-16.88%
1 month	-38.31%
3 months	-15.86%
6 months	+201.26%
Current year	-16.88%

1 week	93.5	119
1 month	93.5	187.5
Current year	93.5	120.4
1 year	20.2	679.5
3 years	20.2	679.5
5 years	20.2	679.5
10 years	20.2	679.5

TransThera Sciences (Nanjing), Inc. Share Price

Equities

2617

CNE100006T02

Biotechnology & Medical Research

Chart: TransThera Sciences (Nanjing), Inc.

Latest news: TransThera Sciences (Nanjing), Inc.

Press Releases: TransThera Sciences (Nanjing), Inc.

Quotes and Performance

Course Extremes

Managers and Directors: TransThera Sciences (Nanjing), Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Manager	Title	Age	Since
Yong Qian Wu CEO	Chief Executive Officer	63	17/11/2016
Song Xi Cui COO	Chief Operating Officer	55	01/08/2021
Jean Fan CTO	Chief Tech/Sci/R&D Officer	62	31/10/2022

Director	Title	Age	Since
Zhong Xin Jia BRD	Director/Board Member	67	10/09/2018
Shu Pai Li BRD	Director/Board Member	49	16/06/2021
Jiang Hua Mei BRD	Director/Board Member	48	15/03/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
TRANSTHERA SCIENCES (NANJING), INC.	+0.26%	-15.56%	-	-	4.85B
ARGENX SE	-0.49%	-0.49%	+8.00%	+87.00%	49.52B
WUXI APPTEC CO., LTD.	+0.71%	+6.24%	+95.76%	+14.62%	44.32B
INSMED INCORPORATED	+1.35%	-8.27%	+121.88%	+744.25%	33.97B
BIONTECH SE	+2.76%	+9.16%	-3.33%	-23.88%	26.62B
GENMAB A/S	+0.97%	+1.63%	+47.09%	-20.95%	20.71B
WUXI BIOLOGICS (CAYMAN) INC.	-0.60%	+9.17%	+128.36%	-45.21%	21.22B
AKESO, INC.	-0.74%	-5.62%	+114.16%	+148.46%	14.4B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.72%	+0.98%	+192.83%	-	14.07B
SUMMIT THERAPEUTICS INC.	-1.33%	-13.41%	-6.32%	+271.24%	13.32B
Average	+0.27%	-1.17%	+77.60%	+146.94%	24.3B
Weighted average by Cap.	+0.38%	+0.80%	+69.97%	+151.55%

	2023	2024
Net sales	1.18M 1.32M 169K 146K 136K 127K 236K 15.38M 254K 1.56M 617K 7.34M 636K 623K 26.78M	-
Net income	-343M -384M -49.28M -42.49M -39.55M -36.82M -68.55M -4.47B -73.76M -455M -179M -2.13B -185M -181M -7.79B	-275M -307M -39.41M -33.98M -31.63M -29.44M -54.82M -3.58B -58.98M -364M -143M -1.71B -148M -145M -6.23B
Net Debt	-	-